PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer
- First Posted Date
- 2002-06-03
- Last Posted Date
- 2014-05-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 4740
- Registration Number
- NCT00038467
- Locations
- 🇬🇧
Pfizer Investigational Site, Wythenshawe, Manchester, United Kingdom
Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia
Phase 3
Completed
- Conditions
- Sarcoma
- First Posted Date
- 2002-05-31
- Last Posted Date
- 2015-05-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 120
- Registration Number
- NCT00038311
- Locations
- 🇺🇸
Pfizer Investigational Site, Houston, Texas, United States
Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen
- First Posted Date
- 2002-05-30
- Last Posted Date
- 2010-02-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 111
- Registration Number
- NCT00038103
- Locations
- 🇵🇭
Pfizer Investigational Site, Manila, Philippines
Irinotecan in Treating Patients With Refractory Solid Tumors and Liver Dysfunction
Phase 1
Completed
- Conditions
- Unspecified Adult Solid TumorChemotherapyLiver DysfunctionNeoplasms, Solid Tumor
- First Posted Date
- 2002-05-22
- Last Posted Date
- 2009-08-14
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00037804
- Locations
- 🇺🇸
Research Center, Marshfield, Wisconsin, United States
Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia
Phase 3
Completed
- Conditions
- NeoplasmsThrombocytopeniaMultiple MyelomaLymphoma, Malignant
- First Posted Date
- 2002-05-22
- Last Posted Date
- 2006-11-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 180
- Registration Number
- NCT00037791
- Locations
- 🇲🇽
Pfizer Investigational Site, Mexico City, DF, Mexico
The Safety and Effectiveness of Intravenous Anidulafungin as a Treatment for Patients With Invasive Candidiasis.
Phase 2
Completed
- Conditions
- Candidiasis
- First Posted Date
- 2002-05-17
- Last Posted Date
- 2008-10-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 120
- Registration Number
- NCT00037219
- Locations
- 🇺🇸
Versicor, Inc., King of Prussia, Pennsylvania, United States
A Safety & Effectiveness Study of Intravenous Anidulafungin With AmBisome® for Treatment of Invasive Aspergillosis (IA).
Phase 2
Completed
- Conditions
- Aspergillosis
- First Posted Date
- 2002-05-17
- Last Posted Date
- 2008-10-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 30
- Registration Number
- NCT00037206
- Locations
- 🇺🇸
Versicor, Inc., King of Prussia, Pennsylvania, United States
For Prevention of Diarrhea in Patients Diagnosed With Metastatic Colorectal Cancer Treated With Chemotherapy
Phase 2
Terminated
- Conditions
- Neoplasm MetastasisColorectal Neoplasms
- First Posted Date
- 2002-05-17
- Last Posted Date
- 2008-09-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 212
- Registration Number
- NCT00037180
- Locations
- 🇺🇸
Pfizer Investigational Site, Milwaukee, Wisconsin, United States
Antibiotic Treatment for Infections of Short Term In-dwelling Vascular Catheters Due to Gram Positive Bacteria
Phase 3
Completed
- Conditions
- Bacterial InfectionsGram-Positive Bacterial InfectionsBacteremia
- First Posted Date
- 2002-05-15
- Last Posted Date
- 2009-09-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 739
- Registration Number
- NCT00037050
Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease.
Phase 3
Completed
- Conditions
- Parkinson Disease
- First Posted Date
- 2002-05-09
- Last Posted Date
- 2006-06-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 600
- Registration Number
- NCT00036218
- Locations
- 🇵🇷
Pfizer Investigational Site, Carolina, Puerto Rico
© Copyright 2025. All Rights Reserved by MedPath